



Exploring Protein-Ligand Interaction: Key Insights for Drug Discovery

Guest Editors:

Dr. Aurica Precupas

“Ilie Murgulescu” Institute of
Physical Chemistry of the
Romanian Academy, Bucharest,
Romania

Dr. Vlad T. Popa

“Ilie Murgulescu” Institute of
Physical Chemistry of the
Romanian Academy, Bucharest,
Romania

Deadline for manuscript
submissions:

31 August 2024

Message from the Guest Editors

Dear Colleagues,

The extensive research into protein aggregation processes may offer significant insight into the key mechanisms of cellular malfunction caused by aggregation, opening new pathways for drug development. The interactions between natural and synthetic ligands/drugs, and organic/inorganic nanoparticles with proteins may lead to: (i) alteration of the biological and pharmacological activities of ligands/drugs, their delivery to cells and tissues, and their potential antioxidant capacity; (ii) partial modifications of protein physiological functions, with loss of their native structure and even inactivation.

This Special Issue is devoted to new contributions into protein–ligand interactions studied under physiological and/or pathological conditions using both experimental and theoretical approaches. Experimental and computational techniques may be taken into consideration. Such studies are essential for understanding biological control mechanisms and provide an experimental and theoretical basis for the discovery, design and development of new drugs and novel therapeutic strategies.

- protein
- ligand
- molecular docking
- molecular dynamics simulation





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)